{
    "clinical_study": {
        "@rank": "78965", 
        "arm_group": {
            "arm_group_label": "BIBF 1120", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study was to determine the maximum tolerated dose (MTD) of\n      BIBF 1120 in patients with solid tumours by the monitoring of drug-related adverse events.\n      Secondary objectives were the evaluation of safety, efficacy, pharmacokinetics, and\n      pharmacodynamics."
        }, 
        "brief_title": "To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours", 
        "condition": "Malignant Solid Tumour", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with confirmed diagnosis of advanced, non resectable and / or metastatic\n             solid tumours, who have failed conventional treatment, or for whom no therapy of\n             proven efficacy exists, or who are not amenable to established forms of treatment\n\n          -  Evaluable tumour deposits by one or more techniques (X-ray, CT, MRI, ultrasound)\n\n          -  Age 18 years or older\n\n          -  Life expectancy of at least three months\n\n          -  Patients had to give written informed consent (which must be consistent with\n             International Conference on Harmonization Good Clinical Practice (ICH-GCP) and local\n             legislation)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance score < 2\n\n          -  Full recovery from all therapy-related toxicities from previous chemo-,\n             hormone-,immuno-, or radiotherapy\n\n        Exclusion Criteria:\n\n          -  History of relevant surgical procedures during the last four weeks prior to treatment\n             with the trial drug, or active ulcers, or injuries with incomplete wound healing\n\n          -  Pregnancy or breastfeeding\n\n          -  Active infectious disease\n\n          -  Brain metastases requiring therapy\n\n          -  Absolute neutrophil count less than 1500 / mm3\n\n          -  Platelet count less than 100 000 / mm3\n\n          -  Bilirubin greater than 1.5 mg / dl (> 26 \u03bcmol / L, International System of Units (SI\n             unit) equivalent)\n\n          -  Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater\n             than three times the upper limit of normal (if related to liver metastases greater\n             than five times the upper limit of normal)\n\n          -  Serum creatinine greater than 1.5 mg / dl (> 132 \u03bcmol / L, SI unit equivalent)\n\n          -  Uncontrolled, severe hypertension\n\n          -  Gastrointestinal disorders anticipated to interfere with the resorption of the study\n             drug\n\n          -  Serious illness or concomitant non-oncological disease considered by the investigator\n             to be incompatible with the protocol\n\n          -  Women and men who are sexually active and unwilling to use a medically acceptable\n             method of contraception\n\n          -  Treatment with other investigational drugs or participation in another clinical trial\n             within the past four weeks before start of therapy or concomitantly with this trial\n             (except for present trial drug)\n\n          -  Patients unable to comply with the protocol\n\n          -  Active alcohol or drug abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "id_info": {
            "nct_id": "NCT01951846", 
            "org_study_id": "1199.1"
        }, 
        "intervention": {
            "arm_group_label": "BIBF 1120", 
            "intervention_name": "BIBF 1120", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Freiburg", 
                    "country": "Germany", 
                    "zip": "79106"
                }, 
                "name": "Klinik f\u00fcr Tumorbiologie, Abteilung Internistische Onkologie"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose of BIBF 1120", 
            "safety_issue": "Yes", 
            "time_frame": "up to 30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951846"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall best investigator assessment of tumour response", 
                "safety_issue": "No", 
                "time_frame": "up to 4 months"
            }, 
            {
                "measure": "Overall best calculated assessment of tumour response", 
                "safety_issue": "No", 
                "time_frame": "up to 4 months"
            }, 
            {
                "measure": "Time to tumour progression", 
                "safety_issue": "No", 
                "time_frame": "up to 4 months"
            }, 
            {
                "measure": "Change in Eastern Cooperative Oncology Group (ECOG) score", 
                "safety_issue": "No", 
                "time_frame": "up to 4 months"
            }, 
            {
                "measure": "Number of patients with response in transfer of contrast medium into tissue (Ktrans)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 months"
            }, 
            {
                "measure": "Number of patients with response in initial area under the curve for first 60 seconds after onset of gadolinium uptake (iAUC60)", 
                "safety_issue": "No", 
                "time_frame": "60 seconds"
            }, 
            {
                "measure": "Mean plasma level of vascular endothelial growth factor (VEGF)", 
                "safety_issue": "No", 
                "time_frame": "10 hours after drug intake"
            }, 
            {
                "measure": "Mean plasma level of basic fibroblast growth factor (bFGF)", 
                "safety_issue": "No", 
                "time_frame": "10 hours after drug intake"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2002", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}